AR117006A1 - Compuesto de 1,3-azol sustituido, composición farmacéutica que lo comprende y su uso para la fabricación de un medicamento - Google Patents

Compuesto de 1,3-azol sustituido, composición farmacéutica que lo comprende y su uso para la fabricación de un medicamento

Info

Publication number
AR117006A1
AR117006A1 ARP190103251A ARP190103251A AR117006A1 AR 117006 A1 AR117006 A1 AR 117006A1 AR P190103251 A ARP190103251 A AR P190103251A AR P190103251 A ARP190103251 A AR P190103251A AR 117006 A1 AR117006 A1 AR 117006A1
Authority
AR
Argentina
Prior art keywords
fluoro
independently selected
substituents independently
substituted
alkyl
Prior art date
Application number
ARP190103251A
Other languages
English (en)
Inventor
Jr Terrence L Smalley
Christie Schulte
Andrew L Larkin
David Norman Deaton
Rodolfo Cadilla
Original Assignee
Glaxosmithkline Ip Dev Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Ip Dev Ltd filed Critical Glaxosmithkline Ip Dev Ltd
Publication of AR117006A1 publication Critical patent/AR117006A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D421/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having selenium, tellurium, or halogen atoms as ring hetero atoms
    • C07D421/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having selenium, tellurium, or halogen atoms as ring hetero atoms containing two hetero rings
    • C07D421/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having selenium, tellurium, or halogen atoms as ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Un compuesto de fórmula (1) en donde Ar¹, R²¹, R²³, R²⁴, R²⁵, R²⁶, R²⁷, A, X, Y y W son como se definen en el presente documento. Los compuestos de la presente son inhibidores de prostaglandina D sintasa hematopoyética (H-PGDS) y pueden ser útiles en el tratamiento de distrofia muscular de Duchenne. Por consiguiente, la presente se refiere además a composiciones farmacéuticas que comprenden un compuesto de la misma. La presente también se refiere además a métodos para inhibir la actividad de H-PGDS y tratamiento de trastornos asociados a la misma usando un compuesto de la presente o una composición farmacéutica que comprende un compuesto de la presente. Reivindicación 1: Un compuesto de 1,3-azol sustituido caracterizado porque tiene la fórmula (1), en donde: Ar¹ se selecciona entre: fenilo, benzofuranilo, pirazolilo, imidazolilo, piridinilo, y pirimidinilo, cada uno de los cuales está opcionalmente sustituido con 1 a 4 sustituyentes seleccionados independientemente entre: fluoro, cloro, bromo, yodo, alquilo C₁₋₃, alquilo C₁₋₃ sustituido con uno a cuatro sustituyentes seleccionados independientemente entre: -OH, oxo y fluoro, -CN, -OH, ciclopropilo, alcoxi C₁₋₃, y alcoxi C₁₋₃ sustituido con uno a cuatro sustituyentes seleccionados independientemente entre: -OH, oxo y fluoro; W se selecciona entre: S y Se; X se selecciona entre: C y N; Y se selecciona entre: -C(O)-, -C(S)-, -C(Se)-, -S(O)- y -S(O₂)-; A se selecciona entre: -C(O)-, -C(S)-, -C(Se)- y -S(O₂)-; R²¹ se selecciona entre: hidrógeno y -CH₃; R²³ y R²⁴ están unidos a átomos de carbono iguales o diferentes y se seleccionan independientemente entre: hidrógeno, alquilo C₁₋₅, alquilo C₁₋₅ sustituido con uno o cuatro sustituyentes independientemente seleccionados entre: -OH, oxo, -NH₂ y fluoro, o R²³ y R²⁴ están unidos al mismo carbono y se toman juntos para formar: ciclopropilo, ciclobutilo, ciclopentilo, oxetanilo, tetrahidrofurano, o tetrahidropirano, o R²³ y R²⁴ están unidos a diferentes átomos de carbono y se toman juntos para formar: ciclopropilo, ciclobutilo, ciclopentilo, oxetanilo, tetrahidrofurano, o tetrahidropirano; R²⁵ se selecciona entre: hidrógeno, alquilo C₁₋₅, alquilo C₁₋₅ sustituido con uno a cuatro sustituyentes independientemente seleccionados entre: -OH, oxo, -NH₂ y fluoro, y alquilarilo C₁₋₅, y alquilarilo C₁₋₅ sustituido con 1 a 3 sustituyentes independientemente seleccionados entre fluoro, cloro, bromo, yodo, alquilo C₁₋₃, alquilo C₁₋₃ sustituido con uno a cuatro sustituyentes independientemente seleccionados entre: -OH, oxo y fluoro, -CN, -OH, ciclopropilo, alcoxi C₁₋₃, y alcoxi C₁₋₃ sustituido con uno a cuatro sustituyentes independientemente seleccionados entre: -OH, oxo y fluoro; R²⁶ se selecciona entre: hidrógeno y -CH₃; y R²⁷ está ausente cuando X es N o se selecciona entre: hidrógeno y -CH₃; o una sal farmacéuticamente aceptable del mismo.
ARP190103251A 2018-11-08 2019-11-06 Compuesto de 1,3-azol sustituido, composición farmacéutica que lo comprende y su uso para la fabricación de un medicamento AR117006A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862757205P 2018-11-08 2018-11-08

Publications (1)

Publication Number Publication Date
AR117006A1 true AR117006A1 (es) 2021-07-07

Family

ID=68542702

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP190103251A AR117006A1 (es) 2018-11-08 2019-11-06 Compuesto de 1,3-azol sustituido, composición farmacéutica que lo comprende y su uso para la fabricación de un medicamento

Country Status (10)

Country Link
US (1) US20220009918A1 (es)
EP (1) EP3877384A1 (es)
JP (1) JP2022506850A (es)
CN (1) CN112969698A (es)
AR (1) AR117006A1 (es)
BR (1) BR112021008976A2 (es)
CA (1) CA3117943A1 (es)
TW (1) TW202039479A (es)
UY (1) UY38455A (es)
WO (1) WO2020095215A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115667259A (zh) 2020-06-19 2023-01-31 佐藤制药株式会社 抑制h-pgds的稠环化合物

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6576265B1 (en) 1999-12-22 2003-06-10 Acell, Inc. Tissue regenerative composition, method of making, and method of use thereof
WO2005094805A1 (ja) 2004-04-01 2005-10-13 Institute Of Medicinal Molecular Design. Inc. イミン誘導体及びアミド誘導体
TW200720255A (en) 2005-07-13 2007-06-01 Taiho Pharmaceutical Co Ltd Benzoimidazole compound capable of inhibiting prostaglandin d synthetase
JP2007051121A (ja) 2005-07-22 2007-03-01 Taiho Yakuhin Kogyo Kk プロスタグランジンｄ合成酵素を阻害するピリミジン化合物
PE20110118A1 (es) 2005-10-04 2011-03-08 Aventis Pharma Inc Compuestos de pirimidina amida como inhibidores de pgds
EP2129660A2 (en) 2006-12-19 2009-12-09 Pfizer Products Inc. Nicotinamide derivatives as inhibitors of h-pgds and their use for treating prostaglandin d2 mediated diseases
SG179437A1 (en) 2007-03-30 2012-04-27 Sanofi Aventis Pyrimidine hydrazide compounds as pgds inhibitors
GB0706793D0 (en) 2007-04-05 2007-05-16 Evotec Ag Compounds
US8334314B2 (en) 2008-04-28 2012-12-18 Asahi Kasei Pharma Corporation Phenylpropionic acid derivative and use thereof
CA2722420A1 (en) 2008-05-13 2009-11-19 Cayman Chemical Company, Incorporated Methods for assaying compounds or agents for ability to displace potent ligands of hematopoietic prostaglandin d synthase
CA2724998A1 (en) 2008-06-18 2009-12-23 Pfizer Limited Nicotinamide derivatives
US20110306597A1 (en) 2008-06-18 2011-12-15 James Michael Crawforth Nicotinamide Derivatives
SG2014014013A (en) 2008-09-22 2014-07-30 Cayman Chemical Co Inc Multiheteroaryl compounds as inhibitors of h-pgds and their use for treating prostaglandin d2 mediated diseases
ES2564454T3 (es) 2009-03-09 2016-03-22 Taiho Pharmaceutical Co., Ltd. Compuesto de piperazina que puede inhibir la prostaglandina D sintasa
WO2011043359A1 (ja) 2009-10-06 2011-04-14 協和発酵キリン株式会社 芳香族複素環化合物を含有する医薬
RU2572608C2 (ru) 2009-10-08 2016-01-20 Санофи Производные фенилоксадиазола в качестве ингибиторов pgds
CA2787248C (en) 2010-01-22 2016-03-01 Taiho Pharmaceutical Co., Ltd. Piperazine compound having a pgds inhibitory effect
TW201326154A (zh) 2011-11-28 2013-07-01 拜耳知識產權公司 作為ｅｐ２受體拮抗劑之新穎２ｈ－吲唑
CA3066979A1 (en) * 2017-06-13 2018-12-20 Glaxosmithkline Intellectual Property Development Limited Chemical compounds as h-pgds inhibitors

Also Published As

Publication number Publication date
US20220009918A1 (en) 2022-01-13
CA3117943A1 (en) 2020-05-14
JP2022506850A (ja) 2022-01-17
UY38455A (es) 2020-05-29
EP3877384A1 (en) 2021-09-15
CN112969698A (zh) 2021-06-15
BR112021008976A2 (pt) 2021-08-03
WO2020095215A1 (en) 2020-05-14
TW202039479A (zh) 2020-11-01

Similar Documents

Publication Publication Date Title
AR109315A1 (es) Composiciones farmacéuticas que contienen derivados de piridona policíclica sustituida y profármaco de las mismas
AR109905A1 (es) Pirrolidinas sustituidas como moduladores de cftr
PE20160126A1 (es) Derivados del bipirazol como inhibidores jak
CL2020001343A1 (es) Nuevos profármacos de catecolamina para uso en el tratamiento de la enfermedad de parkinson.
MX2015017861A (es) Derivados de benzotiofeno como inhibidores del receptor de estrogeno.
NZ721175A (en) Syk inhibitors
UY35641A (es) PROCEDIMIENTO DE SÍNTESIS PARA PREPARAR ANÁLOGOS MACROCÍCLICOS C1-CETO DE HALICONDRINA B, E INTERMEDIARIOS ÚTILES INCLUYENDO INTERMEDIARIOS CONTENIENDO GRUPOS ?SO2-(p-TOLILO)
AR095426A1 (es) Inhibidores tripeptídicos de la epoxicetona proteasa
AR091093A1 (es) Tienopirimidinas
TN2019000204A1 (en) Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same
PH12016500885A1 (en) Novel heterocyclic compounds
PH12016501977A1 (en) 2-AMINO-6-METHYL-4,4a,5,6-TETRAHYDROPYRANO[3,4-d][1,3]THIAZIN-8a(8H)-YL-1,3-THIAZOL-4-YL AMIDES
EA201401082A1 (ru) Фармацевтические препараты, содержащие антагонисты ccr3
BR112020020768A2 (pt) Derivados de pirazol-triazina e/ou pirazol-pirimidina como inibidor seletivo de cinase dependente de ciclina
HRP20220429T1 (hr) Novi antagonisti receptora bradikinina b2
PE20240930A1 (es) Analogos de benzoazepina como agentes inhibidores de la tirosina cinasa de bruton
AR111494A1 (es) Compuestos de anilinoquinazolina c₅ y su uso en el tratamiento del cáncer
AR110241A1 (es) Ácidos indanilaminopiridil-ciclopropano-carboxílicos, composiciones farmacéuticas y usos de los mismos
PH12017502254B1 (en) Pyrazole derivative or pharmaceutically acceptable salt thereof
AR099936A1 (es) Heterociclos condensados sustituidos como moduladores de gpr119 para el tratamiento de la diabetes, obesidad, dislipidemia y trastornos relacionados
PH12019500822A1 (en) Crystalline forms of eravacycline
CL2018000839A1 (es) Derivados de 2-aminoquinazolina como inhibidores de la quinasa p70s6
PE20181328A1 (es) Compuestos de dihidroquinolinsulfonamida de alquilo
AR117006A1 (es) Compuesto de 1,3-azol sustituido, composición farmacéutica que lo comprende y su uso para la fabricación de un medicamento
AR111826A1 (es) Compuestos bicíclicos 5,6 fusionados y composiciones para el tratamiento de las enfermedades parasitarias